◀ Back to RHOA
CD44 — RHOA
Pathways - manually collected, often from reviews:
Text-mined interactions from Literome
Bourguignon et al., J Biol Chem 2003
(Breast Neoplasms...) :
Finally, we have found that overexpression of a dominant negative form of ROK ( by transfection of MBA-MD-231 cells with the Rho binding domain cDNA of ROK ) not only inhibits
HA/CD44 mediated
RhoA-ROK activation and Gab-1 phosphorylation but also down-regulates oncogenic signaling events ( e.g. Gab-1.PI 3-kinase-CD44v3 association, PI 3-kinase mediated AKT activation, and M-CSF production ) and tumor cell behaviors ( e.g. cell growth, survival, and invasion )
Ito et al., Am J Pathol 2004
:
In the presence of HA, TGF-beta1 mediated activation of
RhoA was also abrogated in a
CD44 dependent manner
Heo et al., J Ethnopharmacol 2005
(Melanoma, Experimental) :
Taken together, these results suggest that the Wisteria gall extract may inhibit cancer cell migration via inhibition of
CD44 mRNA expression and
activation of the
GTP-RhoA protein
Bourguignon et al., J Biol Chem 2006
(Carcinoma, Squamous Cell...) :
HA-CD44 binding
induces LARG-specific
RhoA signaling and phospholipase C epsilon ( PLC epsilon ) activity
Wang et al., Arterioscler Thromb Vasc Biol 2013
:
Of the 2 forms of heparanase secreted from EC in response to high glucose, active heparanase released LPL from the myocyte surface, whereas latent heparanase stimulated reloading of LPL from an intracellular pool via
heparan sulfate proteoglycan mediated
RhoA activation